VaxInnate Corporation
3 Cedar Brook Drive
Suite 1
Cranbury
New Jersey
08512
United States
Tel: 609 860 2260
Fax: 609 860 2290
Website: http://www.vaxinnate.com/
45 articles about VaxInnate Corporation
-
X-Vax Technology is ready to submit an IND application to the U.S. FDA for its experimental herpes vaccine against HSV-1 and -2. Here's what you need to know.
-
VaxInnate Corporation To Present At Cantor Fitzgerald's Inaugural Healthcare Conference
7/1/2015
-
VaxInnate Corporation Appoints Former CDC Division Chief Thomas Monath To Board Of Directors
6/17/2015
-
VaxInnate Corporation Advances Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, Into Phase II Study
6/3/2015
-
VaxInnate Corporation Enhances R&D Program and Strengthens Senior Management Team to Drive Pipeline Development of Current and Potential Targets
5/13/2015
-
VaxInnate Corporation To Present At Needham & Company 14th Annual Healthcare Conference
4/7/2015
-
VaxInnate Corporation Receives Extension Of Contract From Biomedical Advanced Research and Development Authority (BARDA) For Development Of Seasonal And Pandemic Influenza Vaccines
2/17/2015
-
VaxInnate Corporation Initiates Phase 1b/2 Clinical Trial Of Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, In Elderly
12/8/2014
-
VaxInnate Corporation Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, Meets Phase 1 Seasonal Influenza Endpoints
11/11/2014
-
VaxInnate Corporation Updates Plans To Advance Lead Vaccine Candidate, VAX2012Q In Elderly
10/8/2014
-
Well-Capitalized VaxInnate Corporation Gets Another $6 Million For Its Bacteria-Based Flu Vaccines
10/3/2014
-
VaxInnate Corporation Begins Phase I Clinical Trial To Evaluate Quadrivalent Vaccine For Prevention Of Seasonal Flu
3/19/2014
-
VaxInnate Corporation Receives $2.1 Million From New Jersey’s Technology Business Tax Certificate Transfer Program
1/28/2014
-
VaxInnate Corporation Awarded U.S. Government Grant to Develop Dengue Vaccine
4/4/2013
-
VaxInnate Corporation’s License Agreement With Emergent BioSolutions Improves U.S. Preparedness for Potential Flu Pandemics
1/16/2013
-
Emergent BioSolutions Secures Exclusive U.S. Commercial Rights to Next Generation Pandemic Influenza Vaccine Candidate
1/2/2013
-
Two New Executives Join VaxInnate Corporation Management Team
9/4/2012
-
VaxInnate Corporation Begins Phase I Clinical Trial to Evaluate H5N1 Vaccine Candidate for Pandemic Avian Flu
6/12/2012
-
VaxInnate Corporation Names Wayne Pisano as its New CEO
4/2/2012
-
VaxInnate Corporation Licenses Recombinant Flu Vaccines to CJ CheilJedang of South Korea
12/19/2011